RTP Mobile Logo
Oncology Today with Dr Neil Love: An interview with Angeles Alvarez Secord, MD, MHSc — Management of Ovarian and Endometrial Cancer (Audio Interview)
Released August 2024

Featuring an interview with Dr Angeles Alvarez Secord. Published August 21, 2024. (Audio Interview)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, gynecologic oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of ovarian and endometrial cancer.

    LEARNING OBJECTIVES

    • Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced ovarian cancer (OC), and provide appropriate counsel regarding personalized treatment recommendations.
    • Assess available clinical trial data with and newly adapted indications for FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiregimen-refractory OC in order to optimally and appropriately incorporate these agents into current treatment algorithms.
    • Evaluate the biological rationale for and published research data with PARP inhibitors in combination with other systemic therapies, and consider the current and future clinical and research implications of these findings for OC management.
    • Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer (EC), and consider the current and future role of this novel strategy in the care of patients with microsatellite instability-high/mismatch repair-deficient and microsatellite-stable/mismatch repair-proficient disease.
    • Recognize available data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and select patients with metastatic EC to receive this novel approach.
    • Understand the biological rationale for and available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC.
    • Evaluate published clinical research findings documenting the efficacy of HER2-targeted agents and regimens in patients with HER2-overexpressing EC, OC and other gynecologic cancers, and consider the role of various approaches in the management of these diseases.
    • Describe the scientific justification for, published research data with and ongoing studies of novel agents and strategies for OC and EC, and effectively prioritize clinical trial opportunities for eligible patients.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Interview: Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Interview: Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1 (audio) and 1 (video) Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
    Successful completion of these CME activities, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

    Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology. 

    PRIVACY POLICY
    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:

    Audio Interview: ResearchToPractice.com/OncologyTodayASCOOvarianEndo24 and evaluation ResearchToPractice.com/OncologyTodayASCOOvarianEndo24/CME.

    Video Interview: ResearchToPractice.com/OncologyTodayASCOOvarianEndo24/Video and evaluation ResearchToPractice.com/OncologyTodayASCOOvarianEndo24/Video/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Angeles Alvarez Secord, MD, MHSc
    Professor of Obstetrics and Gynecology, Gynecologic Oncology
    Director of Gynecologic Oncology Clinical Trials
    Duke Cancer Institute
    Durham, North Carolina

    Clinical Trial Steering Committees (Uncompensated): Aravive Inc (AXLerate trial), CanariaBio Inc (FLORA-5 trial, QPT-ORE-004 trial), F Hoffmann-La Roche Ltd (AtTEnd trial); Contracted Research: AbbVie Inc, Aravive Inc, AstraZeneca Pharmaceuticals LP, CanariaBio Inc, Clovis Oncology, Eisai Inc, Ellipses Pharma, Genentech, a member of the Roche Group, GSK, I-Mab Biopharma, ImmunoGen Inc, Karyopharm Therapeutics, Merck, Mersana Therapeutics Inc, OncoQuest Inc, Seagen Inc, VBL Therapeutics, Zentalis Pharmaceuticals; Data and Safety Monitoring Board/Committee: CanariaBio Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, GSK, Karyopharm Therapeutics, and Merck.

    Release date: August 2024
    Expiration date: August 2025

    After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio
(WIFI is recommended for best performance):